PMN March 21 Tolperisone Muscle Relaxant Randall Kaye
Tolperisone, a skeletal muscle relaxant, was first developed in the mid-20th century in eastern Europe, and has been used throughout the globe since—except in the U.S. Randall Kaye of Neurana Pharmaceuticals talks about his company's journey bringing the drug to the U.S. market, specifically on his research presented at PAINWeek 2020.
Acute Muscle Spasms of the Back
Overview of Muscle Spasm Clinical Features & Presentation
Key Highlights: Acute muscle spasms of the back are sudden, sustained involuntary contractions of muscles or muscle groups localized within the spine. During a lifetime, approximately 84% of US adults (175 million) experience musculoskeletal spasms. A review of muscle spasms and clinical features and presentation.
SEP 11-13, 2020
Tolperisone for Acute Muscle Spasm: Dose-Ranging STAR Study
Srinivas Nalamachu, MD; Randall Kaye, MD; Joseph Pergolizzi, MD
Key Highlights: Tolperisone dose of 200 mg TID may be a promising treatment for the management of acute muscle spasm without the somnolence typically experienced with skeletal muscle relaxants.
NOV 24, 2020
Tolperisone for the Treatment of Acute Muscle Spasm of the Back: Results From the Dose-Ranging Phase 2 STAR Study (NCT03802565)
Srinivas Nalamachu, Joseph Pergolizzi, Randall Kaye
Key Highlights: Tolperisone 200 mg TID may be a promising treatment for management of acute muscle spasm, without the somnolence typically associated with SMRs.
SEP 5, 2020
Novel Form of Muscle Relaxant Shows Benefit
Tolperisone may help pain from acute back spasms without causing drowsiness
Judy George, Senior Staff Writer, MedPage Today September 5, 2020
Key Highlights: Tolperisone, a centrally-acting muscle relaxant, may treat symptoms of acute muscle spasms without the sleepiness and cognitive effects associated with other skeletal muscle relaxants.
SEP 11-13, 2020
Tolperisone 100 and 200 mg Three Times Daily (TID) for Acute Muscle Spasm of the Back: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase 3 Study
Randall Kaye, MD; Henry Riordan, PhD; Srinivas Nalamachu, MD; Joseph Pergolizzi, MD; Sanam Ara Vaughan
Key Highlights: Approximately 750 subjects are planned to be enrolled at about 60 clinical sites in the United States, with the first subject expected to be enrolled in Fall 2020. A second replicate Phase 3 study will be initiated at a later date.
FEB 3, 2020
An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine
Judy Caron PhD; Randall Kaye MD; Thomas Wessel MD, PhD; Amy Halseth PhD; Gary Kay PhD
What is new and conclusion: Subjects who received tolperisone (150 mg TID) experienced no impact on various measures of driving, self-reported sleepiness and cognition measures compared to placebo, in contrast to those who received the widely used muscle relaxant cyclobenzaprine (10 mg TID).